Stem cell clinics selling unproven therapies can expect to face more legal entanglements as federal regulators and law enforcement crack down on what they fear are costly and risky procedures.
The Federal Trade Commission and the Georgia Office of the Attorney General announced this week they’re suing the founders of regenerative medicine companies for allegedly making misleading health claims to target seniors for pain and other orthopedic therapies that cost up to $5,000 per injection.
Separately, the Food and Drug Administration issued a warning letter to a Utah clinic over stem cell treatments derived from umbilical cords. The letter, which ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.